ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drug-Resistant Tuberculosis Treatment Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-15T11609
Home | Market Reports | Health| Health Conditions
Global Drug Resistant Tuberculosis Treatment Market Research Report 2022
BUY CHAPTERS

Global Drug-Resistant Tuberculosis Treatment Market Research Report 2025

Code: QYRE-Auto-15T11609
Report
January 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Novartis
Endo International Plc.
CMP Pharma
Akorn, Incorporated
Lupin Ltd
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
STI Pharma LLC

Drug-Resistant Tuberculosis Treatment Market Size

The global market for Drug-Resistant Tuberculosis Treatment was valued at US$ 2325 million in the year 2024 and is projected to reach a revised size of US$ 3321 million by 2031, growing at a CAGR of 5.3% during the forecast period.

Drug-Resistant Tuberculosis Treatment Market

Drug-Resistant Tuberculosis Treatment Market

Drug-resistant tuberculosis (DR-TB) treatment refers to the medical interventions and therapies used to manage and combat tuberculosis (TB) infections caused by strains of the Mycobacterium tuberculosis bacteria that are resistant to one or more of the standard anti-TB drugs. DR-TB is a significant global health concern because it poses challenges for effective TB control and requires more complex and prolonged treatment regimens compared to drug-susceptible TB. There are different categories of DR-TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), each with its own treatment protocols.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drug-Resistant Tuberculosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug-Resistant Tuberculosis Treatment.
The Drug-Resistant Tuberculosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drug-Resistant Tuberculosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug-Resistant Tuberculosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Drug-Resistant Tuberculosis Treatment Market Report

Report Metric Details
Report Name Drug-Resistant Tuberculosis Treatment Market
Accounted market size in year US$ 2325 million
Forecasted market size in 2031 US$ 3321 million
CAGR 5.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • First-Line Anti-TB Drugs
  • Second-Line Anti-TB Drugs
  • Others
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc., Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Drug-Resistant Tuberculosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Drug-Resistant Tuberculosis Treatment Market growing?

Ans: The Drug-Resistant Tuberculosis Treatment Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the Drug-Resistant Tuberculosis Treatment Market size in 2031?

Ans: The Drug-Resistant Tuberculosis Treatment Market size in 2031 will be US$ 3321 million.

Who are the main players in the Drug-Resistant Tuberculosis Treatment Market report?

Ans: The main players in the Drug-Resistant Tuberculosis Treatment Market are Sanofi, Novartis AG, Endo International plc, CMP Pharma, STI Pharma LLC, Akorn Incorporated, Lupin, Johnson & Johnson Services Inc., Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG

What are the Application segmentation covered in the Drug-Resistant Tuberculosis Treatment Market report?

Ans: The Applications covered in the Drug-Resistant Tuberculosis Treatment Market report are Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others

What are the Type segmentation covered in the Drug-Resistant Tuberculosis Treatment Market report?

Ans: The Types covered in the Drug-Resistant Tuberculosis Treatment Market report are First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs, Others

Recommended Reports

Infectious Disease Drugs

Pulmonary Disease Treatment

Other Disease Therapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 First-Line Anti-TB Drugs
1.2.3 Second-Line Anti-TB Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Drug-Resistant Tuberculosis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug-Resistant Tuberculosis Treatment Market Perspective (2020-2031)
2.2 Global Drug-Resistant Tuberculosis Treatment Growth Trends by Region
2.2.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drug-Resistant Tuberculosis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Drug-Resistant Tuberculosis Treatment Market Dynamics
2.3.1 Drug-Resistant Tuberculosis Treatment Industry Trends
2.3.2 Drug-Resistant Tuberculosis Treatment Market Drivers
2.3.3 Drug-Resistant Tuberculosis Treatment Market Challenges
2.3.4 Drug-Resistant Tuberculosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue
3.1.1 Global Top Drug-Resistant Tuberculosis Treatment Players by Revenue (2020-2025)
3.1.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drug-Resistant Tuberculosis Treatment Revenue
3.4 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio
3.4.1 Global Drug-Resistant Tuberculosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug-Resistant Tuberculosis Treatment Revenue in 2024
3.5 Global Key Players of Drug-Resistant Tuberculosis Treatment Head office and Area Served
3.6 Global Key Players of Drug-Resistant Tuberculosis Treatment, Product and Application
3.7 Global Key Players of Drug-Resistant Tuberculosis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug-Resistant Tuberculosis Treatment Breakdown Data by Type
4.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2026-2031)
5 Drug-Resistant Tuberculosis Treatment Breakdown Data by Application
5.1 Global Drug-Resistant Tuberculosis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drug-Resistant Tuberculosis Treatment Market Size (2020-2031)
6.2 North America Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025)
6.4 North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug-Resistant Tuberculosis Treatment Market Size (2020-2031)
7.2 Europe Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025)
7.4 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug-Resistant Tuberculosis Treatment Market Size (2020-2031)
9.2 Latin America Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025)
9.4 Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Introduction
11.1.4 Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Introduction
11.2.4 Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Endo International plc
11.3.1 Endo International plc Company Details
11.3.2 Endo International plc Business Overview
11.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Introduction
11.3.4 Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.3.5 Endo International plc Recent Development
11.4 CMP Pharma
11.4.1 CMP Pharma Company Details
11.4.2 CMP Pharma Business Overview
11.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Introduction
11.4.4 CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.4.5 CMP Pharma Recent Development
11.5 STI Pharma LLC
11.5.1 STI Pharma LLC Company Details
11.5.2 STI Pharma LLC Business Overview
11.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Introduction
11.5.4 STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.5.5 STI Pharma LLC Recent Development
11.6 Akorn Incorporated
11.6.1 Akorn Incorporated Company Details
11.6.2 Akorn Incorporated Business Overview
11.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Introduction
11.6.4 Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.6.5 Akorn Incorporated Recent Development
11.7 Lupin
11.7.1 Lupin Company Details
11.7.2 Lupin Business Overview
11.7.3 Lupin Drug-Resistant Tuberculosis Treatment Introduction
11.7.4 Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.7.5 Lupin Recent Development
11.8 Johnson & Johnson Services Inc.
11.8.1 Johnson & Johnson Services Inc. Company Details
11.8.2 Johnson & Johnson Services Inc. Business Overview
11.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Introduction
11.8.4 Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.8.5 Johnson & Johnson Services Inc. Recent Development
11.9 Macleods Pharmaceuticals Ltd
11.9.1 Macleods Pharmaceuticals Ltd Company Details
11.9.2 Macleods Pharmaceuticals Ltd Business Overview
11.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.9.4 Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.9.5 Macleods Pharmaceuticals Ltd Recent Development
11.10 Pfizer Inc
11.10.1 Pfizer Inc Company Details
11.10.2 Pfizer Inc Business Overview
11.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Introduction
11.10.4 Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.10.5 Pfizer Inc Recent Development
11.11 Hikma Pharmaceuticals PLC
11.11.1 Hikma Pharmaceuticals PLC Company Details
11.11.2 Hikma Pharmaceuticals PLC Business Overview
11.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Introduction
11.11.4 Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.11.5 Hikma Pharmaceuticals PLC Recent Development
11.12 Lannett
11.12.1 Lannett Company Details
11.12.2 Lannett Business Overview
11.12.3 Lannett Drug-Resistant Tuberculosis Treatment Introduction
11.12.4 Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.12.5 Lannett Recent Development
11.13 Mylan N.V.
11.13.1 Mylan N.V. Company Details
11.13.2 Mylan N.V. Business Overview
11.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Introduction
11.13.4 Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.13.5 Mylan N.V. Recent Development
11.14 Teva Pharmaceutical Industries Ltd
11.14.1 Teva Pharmaceutical Industries Ltd Company Details
11.14.2 Teva Pharmaceutical Industries Ltd Business Overview
11.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Introduction
11.14.4 Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.14.5 Teva Pharmaceutical Industries Ltd Recent Development
11.15 Fresenius Kabi AG
11.15.1 Fresenius Kabi AG Company Details
11.15.2 Fresenius Kabi AG Business Overview
11.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Introduction
11.15.4 Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
11.15.5 Fresenius Kabi AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Sanofi
Novartis
Endo International Plc.
CMP Pharma
Akorn, Incorporated
Lupin Ltd
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
STI Pharma LLC
List of Tables
 Table 1. Global Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of First-Line Anti-TB Drugs
 Table 3. Key Players of Second-Line Anti-TB Drugs
 Table 4. Key Players of Others
 Table 5. Global Drug-Resistant Tuberculosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Drug-Resistant Tuberculosis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Drug-Resistant Tuberculosis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Drug-Resistant Tuberculosis Treatment Market Share by Region (2020-2025)
 Table 9. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Drug-Resistant Tuberculosis Treatment Market Share by Region (2026-2031)
 Table 11. Drug-Resistant Tuberculosis Treatment Market Trends
 Table 12. Drug-Resistant Tuberculosis Treatment Market Drivers
 Table 13. Drug-Resistant Tuberculosis Treatment Market Challenges
 Table 14. Drug-Resistant Tuberculosis Treatment Market Restraints
 Table 15. Global Drug-Resistant Tuberculosis Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Drug-Resistant Tuberculosis Treatment Market Share by Players (2020-2025)
 Table 17. Global Top Drug-Resistant Tuberculosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug-Resistant Tuberculosis Treatment as of 2024)
 Table 18. Ranking of Global Top Drug-Resistant Tuberculosis Treatment Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Drug-Resistant Tuberculosis Treatment, Headquarters and Area Served
 Table 21. Global Key Players of Drug-Resistant Tuberculosis Treatment, Product and Application
 Table 22. Global Key Players of Drug-Resistant Tuberculosis Treatment, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Drug-Resistant Tuberculosis Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type (2020-2025)
 Table 26. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type (2026-2031)
 Table 28. Global Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Application (2020-2025)
 Table 30. Global Drug-Resistant Tuberculosis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Application (2026-2031)
 Table 32. North America Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Sanofi Company Details
 Table 48. Sanofi Business Overview
 Table 49. Sanofi Drug-Resistant Tuberculosis Treatment Product
 Table 50. Sanofi Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 51. Sanofi Recent Development
 Table 52. Novartis AG Company Details
 Table 53. Novartis AG Business Overview
 Table 54. Novartis AG Drug-Resistant Tuberculosis Treatment Product
 Table 55. Novartis AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 56. Novartis AG Recent Development
 Table 57. Endo International plc Company Details
 Table 58. Endo International plc Business Overview
 Table 59. Endo International plc Drug-Resistant Tuberculosis Treatment Product
 Table 60. Endo International plc Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 61. Endo International plc Recent Development
 Table 62. CMP Pharma Company Details
 Table 63. CMP Pharma Business Overview
 Table 64. CMP Pharma Drug-Resistant Tuberculosis Treatment Product
 Table 65. CMP Pharma Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 66. CMP Pharma Recent Development
 Table 67. STI Pharma LLC Company Details
 Table 68. STI Pharma LLC Business Overview
 Table 69. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product
 Table 70. STI Pharma LLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 71. STI Pharma LLC Recent Development
 Table 72. Akorn Incorporated Company Details
 Table 73. Akorn Incorporated Business Overview
 Table 74. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product
 Table 75. Akorn Incorporated Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 76. Akorn Incorporated Recent Development
 Table 77. Lupin Company Details
 Table 78. Lupin Business Overview
 Table 79. Lupin Drug-Resistant Tuberculosis Treatment Product
 Table 80. Lupin Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 81. Lupin Recent Development
 Table 82. Johnson & Johnson Services Inc. Company Details
 Table 83. Johnson & Johnson Services Inc. Business Overview
 Table 84. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product
 Table 85. Johnson & Johnson Services Inc. Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 86. Johnson & Johnson Services Inc. Recent Development
 Table 87. Macleods Pharmaceuticals Ltd Company Details
 Table 88. Macleods Pharmaceuticals Ltd Business Overview
 Table 89. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product
 Table 90. Macleods Pharmaceuticals Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 91. Macleods Pharmaceuticals Ltd Recent Development
 Table 92. Pfizer Inc Company Details
 Table 93. Pfizer Inc Business Overview
 Table 94. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product
 Table 95. Pfizer Inc Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 96. Pfizer Inc Recent Development
 Table 97. Hikma Pharmaceuticals PLC Company Details
 Table 98. Hikma Pharmaceuticals PLC Business Overview
 Table 99. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product
 Table 100. Hikma Pharmaceuticals PLC Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 101. Hikma Pharmaceuticals PLC Recent Development
 Table 102. Lannett Company Details
 Table 103. Lannett Business Overview
 Table 104. Lannett Drug-Resistant Tuberculosis Treatment Product
 Table 105. Lannett Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 106. Lannett Recent Development
 Table 107. Mylan N.V. Company Details
 Table 108. Mylan N.V. Business Overview
 Table 109. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product
 Table 110. Mylan N.V. Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 111. Mylan N.V. Recent Development
 Table 112. Teva Pharmaceutical Industries Ltd Company Details
 Table 113. Teva Pharmaceutical Industries Ltd Business Overview
 Table 114. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product
 Table 115. Teva Pharmaceutical Industries Ltd Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 116. Teva Pharmaceutical Industries Ltd Recent Development
 Table 117. Fresenius Kabi AG Company Details
 Table 118. Fresenius Kabi AG Business Overview
 Table 119. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product
 Table 120. Fresenius Kabi AG Revenue in Drug-Resistant Tuberculosis Treatment Business (2020-2025) & (US$ Million)
 Table 121. Fresenius Kabi AG Recent Development
 Table 122. Research Programs/Design for This Report
 Table 123. Key Data Information from Secondary Sources
 Table 124. Key Data Information from Primary Sources
 Table 125. Authors List of This Report


List of Figures
 Figure 1. Drug-Resistant Tuberculosis Treatment Picture
 Figure 2. Global Drug-Resistant Tuberculosis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drug-Resistant Tuberculosis Treatment Market Share by Type: 2024 VS 2031
 Figure 4. First-Line Anti-TB Drugs Features
 Figure 5. Second-Line Anti-TB Drugs Features
 Figure 6. Others Features
 Figure 7. Global Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Drug-Resistant Tuberculosis Treatment Market Share by Application: 2024 VS 2031
 Figure 9. Hospital Pharmacy Case Studies
 Figure 10. Online Pharmacy Case Studies
 Figure 11. Retail Pharmacy Case Studies
 Figure 12. Others Case Studies
 Figure 13. Drug-Resistant Tuberculosis Treatment Report Years Considered
 Figure 14. Global Drug-Resistant Tuberculosis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Drug-Resistant Tuberculosis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Drug-Resistant Tuberculosis Treatment Market Share by Region: 2024 VS 2031
 Figure 17. Global Drug-Resistant Tuberculosis Treatment Market Share by Players in 2024
 Figure 18. Global Top Drug-Resistant Tuberculosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug-Resistant Tuberculosis Treatment as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue in 2024
 Figure 20. North America Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Drug-Resistant Tuberculosis Treatment Market Share by Country (2020-2031)
 Figure 22. United States Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Drug-Resistant Tuberculosis Treatment Market Share by Country (2020-2031)
 Figure 26. Germany Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Share by Region (2020-2031)
 Figure 34. China Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Drug-Resistant Tuberculosis Treatment Market Share by Country (2020-2031)
 Figure 42. Mexico Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Share by Country (2020-2031)
 Figure 46. Turkey Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Drug-Resistant Tuberculosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Sanofi Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 50. Novartis AG Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 51. Endo International plc Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 52. CMP Pharma Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 53. STI Pharma LLC Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 54. Akorn Incorporated Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 55. Lupin Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 56. Johnson & Johnson Services Inc. Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 57. Macleods Pharmaceuticals Ltd Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 58. Pfizer Inc Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 59. Hikma Pharmaceuticals PLC Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 60. Lannett Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 61. Mylan N.V. Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 62. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 63. Fresenius Kabi AG Revenue Growth Rate in Drug-Resistant Tuberculosis Treatment Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Tuberculosis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Tuberculosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tuberculosis TB Detection Market Research Report 2024
Global Anti tuberculosis Therapeutics Market Insights Forecast to 2030
Global Antimycobacterial Drugs Market Research Report 2024
Global Mycobacterium Tuberculosis Testing Market Research Report 2024
Tuberculosis Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tuberculosis TB Treatment Market Insights Forecast to 2030
Global Tuberculosis TB Diagnostics Market Research Report 2025
Multidrug Resistant Bacteria Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Methicillin Resistant Staphylococcus Aureus MRSA Treatment Market Research Report 2024
Global Mycobacterium Tuberculosis Detection Kits Market Research Report 2025
Tuberculosis Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Drug Resistance Bacterial Infection Treatment Market Insights Forecast to 2030
Antibacterial Drug Resistance Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ocular Tuberculosis Therapeutics Market Research Report 2024
Global Antibiotic Resistance Market Insights Forecast to 2030
Treatment Resistant Depression Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
TB Vaccine Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TB Disease Vaccine Market Research Report 2025

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions